233 related articles for article (PubMed ID: 38468434)
21. Characteristics and Outcomes of US Veterans With Immunocompromised Conditions at High Risk of SARS-CoV-2 Infection With or Without Receipt of Oral Antiviral Agents.
Gentry CA; Nguyen PN; Thind SK; Kurdgelashvili G; Williams RJ
Clin Infect Dis; 2024 Feb; 78(2):330-337. PubMed ID: 37619991
[TBL] [Abstract][Full Text] [Related]
22. Association of nirmatrelvir/ritonavir and remdesivir as treatment for SARS-CoV-2 infection in immunocompromised patients with hematologic malignancies. Series of four cases.
Segura Fábrega A; Pérez Catalán I; Gómez Alfaro I; García Muñoz S; Roig Martí C; Rodríguez Lozano N; Folgado Escudero S; Varea Villanueva M; Gascón Buj A; Torres García M; Reig Valero R; Ferrando Piqueres R; Usó Blasco J
Rev Esp Quimioter; 2023 Dec; 36(6):655-657. PubMed ID: 37786958
[TBL] [Abstract][Full Text] [Related]
23. Dual combined antiviral treatment with remdesivir and nirmatrelvir/ritonavir in patients with impaired humoral immunity and persistent SARS-CoV-2 infection.
Pasquini Z; Toschi A; Casadei B; Pellegrini C; D'Abramo A; Vita S; Beccacece A; Bussini L; Chionsini MC; Dentale N; Cantiani A; Lazzarotto T; Bartoletti M; Nicastri E; Zinzani P; Giannella M; Viale P
Hematol Oncol; 2023 Dec; 41(5):904-911. PubMed ID: 37452579
[TBL] [Abstract][Full Text] [Related]
24. Evaluation of physicians prescribing of COVID-19 guideline-directed outpatient treatments in a primary care walk-in clinic.
Denning K; Sheppard J; Carico R
J Am Pharm Assoc (2003); 2024; 64(2):530-534. PubMed ID: 38151202
[TBL] [Abstract][Full Text] [Related]
25. Safety Profile and Clinical and Virological Outcomes of Nirmatrelvir-Ritonavir Treatment in Patients With Advanced Chronic Kidney Disease and Coronavirus Disease 2019.
Chan GCK; Lui GCY; Wong CNS; Yip SST; Li TCM; Cheung CSK; Sze RKH; Szeto CC; Chow KM
Clin Infect Dis; 2023 Nov; 77(10):1406-1412. PubMed ID: 37531093
[TBL] [Abstract][Full Text] [Related]
26. Nirmatrelvir combined with ritonavir for preventing and treating COVID-19.
Reis S; Metzendorf MI; Kuehn R; Popp M; Gagyor I; Kranke P; Meybohm P; Skoetz N; Weibel S
Cochrane Database Syst Rev; 2023 Nov; 11(11):CD015395. PubMed ID: 38032024
[TBL] [Abstract][Full Text] [Related]
27. Real-world effectiveness of nirmatrelvir-ritonavir versus azvudine in hospitalized patients with COVID-19 during the omicron wave in Beijing: a multicenter retrospective cohort study.
Han X; Gao D; Li C; Yuan X; Cui J; Zhao W; Xie F; Wang K; Liu Y; Muo G; Xi N; Zheng M; Wang R; Xiao K; Zhao D; Zhang X; Han X; Wang B; Zhang T; Xie W; Xie L
BMC Infect Dis; 2024 Jan; 24(1):57. PubMed ID: 38191304
[TBL] [Abstract][Full Text] [Related]
28. Exploring the Use of Monoclonal Antibodies and Antiviral Therapies for Early Treatment of COVID-19 Outpatients in a Real-World Setting: A Nationwide Study from England and Italy.
Ciccimarra F; Luxi N; Bellitto C; L' Abbate L; De Nardo P; Savoldi A; Yeomans A; Molokhia M; Tacconelli E; Trifirò G
BioDrugs; 2023 Sep; 37(5):675-684. PubMed ID: 37148526
[TBL] [Abstract][Full Text] [Related]
29. Analysis of All-Cause Hospitalization and Death Among Nonhospitalized Patients With Type 2 Diabetes and SARS-CoV-2 Infection Treated With Molnupiravir or Nirmatrelvir-Ritonavir During the Omicron Wave in Hong Kong.
Lui DTW; Chung MSH; Lau EHY; Lau KTK; Au ICH; Lee CH; Woo YC; Wong CKH; Cowling BJ
JAMA Netw Open; 2023 May; 6(5):e2314393. PubMed ID: 37204790
[TBL] [Abstract][Full Text] [Related]
30. Synergistic Activity of Remdesivir-Nirmatrelvir Combination on a SARS-CoV-2 In Vitro Model and a Case Report.
Gidari A; Sabbatini S; Schiaroli E; Bastianelli S; Pierucci S; Busti C; Saraca LM; Capogrossi L; Pasticci MB; Francisci D
Viruses; 2023 Jul; 15(7):. PubMed ID: 37515263
[TBL] [Abstract][Full Text] [Related]
31. Mild SARS-CoV-2 infection in vulnerable patients: implementation of a clinical pathway for early treatment.
Pinargote-Celorio H; Otero-Rodríguez S; González-de-la-Aleja P; Rodríguez-Díaz JC; Climent E; Chico-Sánchez P; Riera G; Llorens P; Aparicio M; Montiel I; Boix V; Moreno-Pérez Ó; Ramos-Rincón JM; Merino E
Enferm Infecc Microbiol Clin (Engl Ed); 2024 Apr; 42(4):195-201. PubMed ID: 37003904
[TBL] [Abstract][Full Text] [Related]
32. Effectiveness of nirmatrelvir-ritonavir on severe outcomes of COVID-19 in the era of vaccination and Omicron: An updated meta-analysis.
Ombelet S; Castanares-Zapatero D; Desimpel F; Hulstaert F; Stordeur S; Roberfroid D
J Med Virol; 2024 Feb; 96(2):e29434. PubMed ID: 38376947
[TBL] [Abstract][Full Text] [Related]
33. In outpatients with COVID-19 during Omicron variant circulation, molnupiravir and nirmatrelvir-ritonavir improved outcomes.
Chagla Z
Ann Intern Med; 2024 Jan; 177(1):JC7. PubMed ID: 38163374
[TBL] [Abstract][Full Text] [Related]
34. The effect of nirmatrelvir-ritonavir on viral clearance and length of hospital stay in patients infected with SARS-CoV-2 omicron variants.
Wang Y; Zhao D; Chen X; Liu X; Xiao W; Feng L
Influenza Other Respir Viruses; 2023 Feb; 17(2):e13095. PubMed ID: 36843224
[TBL] [Abstract][Full Text] [Related]
35. Innovative Randomized Phase I Study and Dosing Regimen Selection to Accelerate and Inform Pivotal COVID-19 Trial of Nirmatrelvir.
Singh RSP; Toussi SS; Hackman F; Chan PL; Rao R; Allen R; Van Eyck L; Pawlak S; Kadar EP; Clark F; Shi H; Anderson AS; Binks M; Menon S; Nucci G; Bergman A
Clin Pharmacol Ther; 2022 Jul; 112(1):101-111. PubMed ID: 35388471
[TBL] [Abstract][Full Text] [Related]
36. Efficacy and safety of antiviral treatments for symptomatic COVID-19 outpatients: Systematic review and network meta-analysis.
Zur M; Peselev T; Yanko S; Rotshild V; Matok I
Antiviral Res; 2024 Jan; 221():105768. PubMed ID: 38056602
[TBL] [Abstract][Full Text] [Related]
37. Use of Oral Antivirals Ritonavir-Nirmatrelvir and Molnupiravir in Patients with Multiple Myeloma Is Associated with Low Rates of Severe COVID-19: A Single-Center, Prospective Study.
Spiliopoulou V; Ntanasis-Stathopoulos I; Malandrakis P; Gavriatopoulou M; Theodorakakou F; Fotiou D; Migkou M; Roussou M; Eleutherakis-Papaiakovou E; Kastritis E; Dimopoulos MA; Terpos E
Viruses; 2023 Mar; 15(3):. PubMed ID: 36992413
[TBL] [Abstract][Full Text] [Related]
38. Antiviral efficacy of molnupiravir versus ritonavir-boosted nirmatrelvir in patients with early symptomatic COVID-19 (PLATCOV): an open-label, phase 2, randomised, controlled, adaptive trial.
Schilling WHK; Jittamala P; Watson JA; Boyd S; Luvira V; Siripoon T; Ngamprasertchai T; Batty EM; Cruz C; Callery JJ; Singh S; Saroj M; Kruabkontho V; Ngernseng T; Tanglakmankhong N; Tubprasert J; Abdad MY; Madmanee W; Kouhathong J; Suwannasin K; Pagornrat W; Piaraksa N; Hanboonkunupakarn P; Hanboonkunupakarn B; Poovorawan K; Potaporn M; Srisubat A; Loharjun B; Taylor WRJ; Chotivanich V; Chotivanich K; Imwong M; Pukrittayakamee S; Dondorp AM; Day NPJ; Teixeira MM; Piyaphanee W; Phumratanaprapin W; White NJ;
Lancet Infect Dis; 2024 Jan; 24(1):36-45. PubMed ID: 37778363
[TBL] [Abstract][Full Text] [Related]
39. The Antiviral Effect of Nirmatrelvir/Ritonavir during COVID-19 Pandemic Real-World Data.
Petrakis V; Rafailidis P; Trypsianis G; Papazoglou D; Panagopoulos P
Viruses; 2023 Apr; 15(4):. PubMed ID: 37112956
[TBL] [Abstract][Full Text] [Related]
40. Adaptative Strategy of Immunosuppressive Drugs Dosage Adjustments When Combined With Nirmatrelvir/Ritonavir in Solid Organ Transplant Recipients With COVID-19.
Boland L; Devresse A; Monchaud C; Briol S; Belaiche S; Giguet B; Couzi L; Thaunat O; Esposito L; Meszaros M; Roussoulieres A; Haufroid V; Le Meur Y; Lemaitre F
Transpl Int; 2024; 37():12360. PubMed ID: 38596505
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]